News articles about Exactech (NASDAQ:EXAC) have been trending positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exactech earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 47.4616901010649 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Exactech remained flat at $$49.25 during mid-day trading on Thursday, according to Marketbeat Ratings. 255,640 shares of the stock traded hands, compared to its average volume of 182,742. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. Exactech has a 12 month low of $23.75 and a 12 month high of $50.95.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.